Copenhagen, Denmark: The Novo Nordisk Foundation today announced the latest edition of its annual Challenge Programme, where for the first time it is inviting researchers from outside Denmark, in the European Schengen area, Ireland and the UK, to lead collaborations applying for grants to study four major themes. As part of its ongoing internationalisation, the […]
Novo Holdings and the Export and Investment Fund of Denmark (EIFO) have jointly invested €48 million in HealthCap IX, a Swedish life sciences venture fund focused on building innovative companies in areas of high unmet medical need. Following the investment, HealthCap will establish a local presence in Copenhagen at the BioInnovation Institute (BII) to increase […]
Copenhagen, Denmark – Novo Holdings today announced its financial results for 2024.* Record returns from the Investment Portfolio and growth of the Novo Group companies drive Total Income and Investment Returns to DKK 60 billion (€8.0 billion) for 2024, up from DKK 31 billion (€4.2 billion) in 2023. The Investment Portfolio generated a return of […]
DKK 320 million has been awarded for the development of a new campus that will provide the setting for close collaboration between educational institutions while offering students real-world experience through close interaction with industry. The Novo Nordisk Foundation is committing up to DKK 202 million over a five-year period. With the initiative, industry and educational […]
– ZT002 was safe and well tolerated in both biweekly and monthly dosing arms in patients with overweight or obesity with a tolerability profile aligned with the GLP-1RA class – The open-label extension with ZT002 120 mg, once-monthly, showed 17.1% reduction in body weight at 30 weeks Beijing, China, 12 September 2024 – Beijing QL […]
